toripalimab + surufatinib + chemotherapy

Toripalimab + surufatinib + chemotherapy is an investigational combination regimen being evaluated for the second-line treatment of advanced RAS/BRAF mutant and microsatellite stable (MSS) metastatic colorectal cancer. Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore T-cell activity. Surufatinib is a small-molecule inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R). The addition of surufatinib is intended to modulate the tumor microenvironment and enhance the efficacy of toripalimab and standard chemotherapy (such as oxaliplatin or irinotecan-based regimens). This specific combination was the focus of the Phase 2 APHRODITE study (NCT04653480) conducted at The First Affiliated Hospital, Zhejiang University School of Medicine, which aimed to address the limited efficacy of immunotherapy in MSS colorectal cancer patients.

Brand names

TuoyiLoqtorziSulandaZytorvi

Other names

APHRODITE regimentoripalimab-Zhejiang University-colorectal cancer